Skip to main content
OpenTrials
Completed

NCT Number: NCT05010655

Low Ejection Fraction in Single Lead ECG

The purpose of this research is to prospectively test and validate the single-lead Low EF algorithm in outpatients in order to test the performance of a single-lead ECG based algorithm to identify people with decreased left ventricular EF.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Prairie Cardiovascular Consultants, O'Fallon, Illinois, United States

Loading trial locations.

About this study

Heart failure with reduced left ventricular ejection fraction (EF) is a relatively common cardiac pathology with major clinical implications. People with reduced left ventricular EF are at increased risk for sudden death, ventricular and atrial arrhythmias, and acute hemodynamic decompensation due to heart failure. There are proven medical interventions that prevent sudden cardiac death and complications in people with decreased left ventricular EF. Unfortunately, some people with decreased left ventricular EF are asymptomatic, or have non-specific symptoms like dyspnea, and would not receive those interventions in a timely manner. Currently, there are no effective ways to screen for asymptomatic decreased left ventricular EF in the population, because detection of low EF requires the use of echocardiography. There is a significant need to identify novel technologies that can help to detect people with decreased left ventricular EF in a simple, effective, and reliable manner.

Eko Devices features a cloud-based platform of point-of-care cardiac screening devices and machine learning algorithms that enables more effective detection and management of cardiovascular disease. In this study, we will use the Eko DUO device to collect single-lead ECG data.

The Eko DUO is an FDA-cleared and CE-marked electronic stethoscope that allows audio recording of heart sound to produce a phonocardiogram (PCG) as well as recording a single-lead electrocardiogram (ECG). The DUO features 60x audio amplification, ambient noise reduction, a 4000Hz sample rate, and 4 audio filters. The ECG component is made up of 2 stainless steel electrodes, 0.01Hz high-pass filter, selectable 50/60Hz mains filter, and a 500Hz sample rate. The de-identified auscultatory DUO recordings transmit wirelessly via Bluetooth to the secure, HIPAA-compliant Eko application on a smartphone or tablet, which allows the user to playback heart sound recordings, annotate notes on recorded audio, and save recordings. This data is synced in real-time to a secure, HIPAA-compliant, cloud-based Amazon Web Services (AWS) database server managed by Eko Devices.

It has been previously demonstrated that artificial intelligence processing information from a 12-lead ECG can help to identify people with decreased left ventricular EF1. Using paired 12-lead ECG and echocardiogram data, including the left ventricular ejection fraction, from 44,959 patients at the Mayo Clinic, a convolutional neural was trained to identify patients with low ejection fraction. When tested on an independent set of 52,870 patients, the model showed an Area Under the Curve ("AUC") of 0.93 and an accuracy of 86%. We have also developed a single-lead version of the same algorithm, which will be more easily accessible in a clinical setting since it can be used with a single-lead ECG device like the Eko DUO device. We propose to validate performance of this new model using the current study.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • English-speaking adults who are 18 years and older
  • Able and willing to provide informed consent
  • Complete a clinical echocardiogram within 7 days before or after study procedures

Exclusion criteria

  • Unwilling or unable to provide informed consent
  • Patients who are hospitalized

Treatment and study plan

Use of Eko DUO electronic Stethoscope

Device

Auscultation of heart sounds using electronic stethoscope

Primary outcomes

  1. Single-lead ECG based algorithm development

    Time frame: Within two minutes of device use

    Evaluate performance of single-lead ECG based algorithm to identify individuals with reduced ejection fraction.

Sponsors and collaborators

Lead sponsor

Eko Devices, Inc.

Industry

Registry information

Official study title

Detection of Reduced Left Ventricular Ejection Fraction and Atrial Arrhythmias With Single Lead ECG Using Artificial Intelligence

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Aug 18, 2021
Registry last updated
Dec 9, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.